Merkel Cell Carcinoma (MCC) Treatment Market: Introduction
- Merkel cell carcinoma, also known as neuroendocrine carcinoma of the skin, is a rare and aggressive type of skin cancer that develops from the top layers of the skin. The disease is caused due to prolonged exposure to the sun, weak immunity, or due to idiopathic reasons.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56184
- Merkel cell carcinoma (MCC) is a rare disease in which malignant cancer cells form in the skin. Merkel cell carcinoma is the second-most common cause of skin cancer death after melanoma. Weak immune system and exposure to the sun induce the effects of merkel cell carcinoma. MCC usually appears as a single painless lump when exposed to the sun. The disease starts in areas of skin exposed to the sun, especially the head and neck, as well as the arms, legs, and trunk. Merkel cell carcinoma grows rapidly into a metastasize at an early stage, by spreading to nearby lymph nodes or skin in distant parts of the body, lungs, brain, bones, or other organs.
- Several tests and procedures can be carried to examine the skin to detect and diagnose carcinoma cells; however, there are certain factors or effects of prognosis and treatment options that decrease the chance of recovery. New developments in skin biopsy approaches enable to image the diseases or infection at the cellular and molecular level, paving the way for early diagnosis and treatment of diseases.
Request COVID Analysis on Merkel Cell Carcinoma (MCC) Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=56184
Key Drivers, Restraints, and Opportunities of Global Merkel Cell Carcinoma (MCC) Treatment Market
- Increasing cases of MCC is a prominent factor propelling the global Merkel cell carcinoma market. As per the report published in the Current Dermatology Reports journal, the estimated annual prevalence of MCC was approximately 0.6 per 100,000 people. The National Cancer Database, has reported that each year approximately 2500 and 1500, novel MCC cases are reported in Europe and the U.S., respectively.
- Rising research and development activities for the treatment of Merkel cell carcinoma is anticipated to propel the market. In May 2017, researchers of Fred Hutchison University and the University of Washington in Seattle reported the results of a small study combining Avelumab with two other treatments. The combination therapy improves T cells generation and attacks the MCC cells. The National Cancer Institute has also commenced a clinical trial involving the investigational study of the drug ipilimumab Merkel cell carcinoma. Curalso recently is in phase 2 clinical study.
- The Merkel cell carcinoma pipeline is anticipated to propel the market. For instance, in December 2018, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., undertook a phase 3 open-label, single-arm study to evaluate the efficacy of pembrolizumab as first-line therapy in the participants with advanced Merkel cell carcinoma. In December 2018, Incyte Corporation undertook a phase 2 study of INCMGA00012 in participants with metastatic Merkel cell carcinoma.
- The presence of biosimilars for the Merkel cell carcinoma therapy have been observed to fuel the market. For instance, the European Commission approved the first biosimilars Amgevita, from the Amgen pharmaceutical company. It was approved in the US by the FDA, in September 2016.
- However, the high price of therapeutics, lack of awareness among the people, the onset of side-effects are likely to hamper the market during the forecast period. Side-effects of external radiation therapy include nausea, skin changes, diarrhoea, painful sores in the throat and mouth, fatigue, and dry mouth or thick saliva. The side-effects of the radiation are temporary; however, some rare serious side-effects could become permanent. In a few cases, radiation to the chest could even cause lung damage, which may lead to breathing issues and shortness of breath.
Request Customization on Merkel Cell Carcinoma (MCC) Treatment Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=56184
North America to Capture Major Share of Global Merkel Cell Carcinoma (MCC) Treatment Market
In terms of region, the global merkel cell carcinoma treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global market due to an increase in funding for the development of research and healthcare infrastructure in the region. Rising incidence of skin cancer diseases, such as MCC, and early phase diagnosis and treatment of diseases are driving the biotechnology & pharmaceutical sector in North America, which in turn is expected to boost the Merkel cell carcinoma (MCC) treatment market in the region in the next few years. Europe is the second-leading market for Merkel cell carcinoma treatment, as there are favorable government policies regarding the development of healthcare infrastructure, well-developed facilities for cancer patients, and increasing number of gene therapy companies in the region. The Merkel cell carcinoma (MCC) treatment market in Asia Pacific is projected to expand at a rapid pace during the forecast period due to rising environmental pollution, changing lifestyle of people, increasing awareness among patients about MCC treatment, and growing per capita expenditure for health insurance in the region. Moreover, economic growth in India and China is boosting healthcare infrastructure as well as expansion of pharmaceutical companies and biotech labs, which is likely to drive the Merkel cell carcinoma (MCC) treatment market in Asia Pacific in the near future.
Pre Book Merkel Cell Carcinoma (MCC) Treatment Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=56184<ype=S
Key Players Operating in Global Merkel Cell Carcinoma (MCC) Treatment Market
The global merkel cell carcinoma (MCC) treatment market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global merkel cell carcinoma (MCC) treatment market are:
- Pfizer Inc.
- Ono Pharmaceutical Co. Ltd
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Amgen Inc.
- AstraZeneca
- Novartis AG
- Oncovir, Inc.
- Teva Pharmaceuticals Industries Ltd
- OncoSec Medical Incorporated
- Biologics, Inc. (McKesson Corporation)
- Millennium Pharmaceuticals, Inc.
- NantKwest, Inc.
- Merck KGaA
- BeiGene Ltd.
- Apcure SAS
- Immune Design Corp.
- Others
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com
Global Merkel Cell Carcinoma Market Research Report: By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), Treatment (Surgery, Radiation Therapy, Chemotherapy), End User (Hospitals & Clinics, Diagnostic Centers) – Forecast till 2027Market Synopsis:Market Research Future (MRFR)’s latest study reveals that the global merkel cell carcinoma market is projected to strike a CAGR of 7.40% during the forecast period.
The growing geriatric population is likely to dictate the growth of the market as this disease majorly affects the elderly population.Merkel cell carcinoma poses a high risk of recurrence and metastasis, which has intensified the need for advanced treatments.
It can also be caused by prolonged exposure to the sun.
The rising burden of the disease is expected to propel the expansion of the merkel cell carcinoma market over the assessment period.Key players are emphasizing on the development of highly precise and effective drugs.
Nevertheless, the high cost of therapeutics, side effects of treatment, low healthcare expenditure in developing and underdeveloped nations, and lack of awareness are presumed to hinder the proliferation of the merkel cell carcinoma market in the foreseeable future.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5343 Market Segmentation:By diagnosis, the merkel cell carcinoma market has been segmented into physical examination, sentinel node biopsy, imaging tests, and others.
The chemotherapy segment is sub-segmented into cisplatin, etoposide, and others.By end user, the merkel cell carcinoma market has been segmented into hospitals & clinics, research organization, diagnostic centers, and others.Regional Analysis:The global merkel cell carcinoma market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa.
Market HighlightsFactors driving the growth of the market for the merkel cell carcinoma treatment are the increase in the market for the treatment of merkel cell carcinoma worldwide will affect the demand for innovative drugs for the treatment of metastatic merkel cell carcinoma In addition, high acceptance of immunotherapy and favorable reimbursement are considered to be positive indicators for the growth of the treatment of advanced merkel cell carcinoma.
In comparison, with extended sun exposure, the chance of contracting the disease increases.
Factors such as the growing prevalence of neuroendocrine carcinoma and the increasing geriatric population are also expected to be the key factors over the projected timeframe for business growth.
In addition, growing R investment by key industry participants, rising MCC mortality rates, and rising healthcare spending are some of the factors driving market growth during the projected period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5343However, it is assumed that the market for the treatment of Merkel cell carcinoma is greatly hampered by the high cost of treatment coupled with the cessation of late-stage clinical trials.
It is estimated that the associated side effects, lack of awareness, and low per capita healthcare spending in middle and low-income countries will limit market growth during the forecast period.Segmental AnalysisBased on diagnosis, treatment, and end users, the global market for Merkel cell carcinoma is segmented.
The segment of chemotherapy is sub-segmented to include etoposide, cisplatin, and others.
Market HighlightsThe Global Surgical Retractors Market held a market value of USD 1,103 Million in 2017 and is projected to grow at a CAGR of 7.8% over the forecast period.An increasing number of surgical procedures leading to increase demand of surgical retractors.
Surgical retractors are one of the important surgical instruments which is used to separate the edges of the wound or surgical incision.
Due to increasing prevalence of obesity across the globe many of the companies are in the race to introduce better treatment for obesity.
Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth.
As per the data by the Office for National Statistics, in 2016, the gross domestic expenditure on research and development (R) was Euro 33.1 billion (USD 35.2 billion) in the UK.
Europe is expected to hold the second-largest position in the global surgical retractors market owing to the presence of strong academic & research base and availability of funding for research in the European countries.
Basal cell carcinoma is one of the most common types of skin cancers observed around the world.
Conventionally, the disease has been treated with procedures such as standard surgical excisions, and curettage.
The risk of contracting the disease increases among people who have immunosuppression issues, fair skin, genetic disorders, exposure to ultraviolet light, and a history of BCC.The global basal cell carcinoma treatment market is projected to grow at an impressive CAGR of 9 per cent through the forecast period till 2025.
This growth can be attributed to the increased investments being made by healthcare and pharmaceutical industries into the development of better drug formulations, with the aim of cutting down the risk of basal cell carcinoma.Increased Use of Contract Research Organizations and Radiotherapy Gain TractionCountries in the Asia Pacific and North America regions are expected to display a high potential for growth for the basal cell carcinoma treatment market, which can be attributed to the rising patient awareness about the ailment and the recent advancements and growing range of treatment options including Mohs micrographic surgery, superficial field therapies, and electrodessication.In addition, a number of contract research organizations such as the Skin Cancer Foundation have come up, which have been pushing to increase awareness about the cancer, while also creating training programs for health care professionals for the correct implementation of new treatment options.Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S_id=4366Further, countries in the Asia Pacific region are expected to generate substantial revenue generation opportunities, in comparison numerous regions in such treatment markets on a global scale.
Contract research organizations are also providing new information and insight on treatments such as radiotherapy, which is substantially influencing the landscape of the market.Non-invasive Treatments are Major ContributorsWhile surgical treatments have been the most popular conventionally, patients are increasingly preferring to opt for non-invasive treatments such as superficial radiation therapy (SRT) as such treatment results in lesser risk of complications.In addition, delays in treating basal cell carcinoma can result in issues with bone, skin, and muscle damage, which has also contributed to the increased adoption of SRT over the increasingly impractical practice of radiotherapy.In addition, the older conventional methods and machines of SRT has become obsolete, and create challenges in terms of operations and maintenance.
Consequently, modernization of these equipment is working as a catalyst to the growth of the global basal cell carcinoma market.SRT has been found to result in better outcomes for the patients, as treatments can only impact cancer cells, leaving healthy cells unaffected.
This report studies the global market size of Merkel Cell Carcinoma Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Merkel Cell Carcinoma Treatment in these regions.
This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.
Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin.
The key manufacturers in the Merkel Cell Carcinoma Treatment include
Market Size Split by Type
Market Size Split by Application
